lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
TORREY PINES INVESTMENT
Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
March 17, 2026
Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
February 2, 2026
Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance TMEM175 Agonists for Parkinson’s Disease
January 27, 2026
Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program
January 15, 2026
Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development
December 30, 2025
Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026
December 22, 2025
Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes
December 19, 2025
Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
November 9, 2025
Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.
November 9, 2025
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology
November 7, 2025
1
2
Next Page
→